Physician profile
Paul E Schwartz
NPI 1396770731
$223.33
in general payments reported to CMS, 2019-2025
10 companies · $17.51 in 2025
The $17.51 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.34 · 2020: $31.38 · 2021: $63.26 · 2022: $46.97 · 2023: $25.11 · 2024: $15.76 · 2025: $17.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $58.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $58.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.70 | 2022-2023 | |
| Sunovion Pharmaceuticals INC. | $42.95 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.85 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.65 | 2021 | |
| Lilly USA, LLC | $17.51 | 2025 | Kisunla |
| Amarin Pharma, INC. | $14.93 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $14.35 | 2021 | |
| Medtronic, INC. | $13.33 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.29 | 2022 | |
| Pfizer INC. | $11.77 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.